Novartis has signed a licensing deal with Chinese biotech Abogen Biosciences worth up to $7.8 billion for ABO2203, an mRNA-encoded T-cell engager aimed at autoimmune disease. We break down the $575 million upfront, the in-vivo production approach, early clinical signals, why the risk profile looks different, and the larger pattern of big pharma writing large checks for Chinese RNA platforms.
This is the shift: mRNA moving beyond vaccines into chronic disease and immune reset.
Subscribe for more deals where money meets medicine.
Show notes:
• Deal structure and numbers
• How ABO2203 works (mRNA-encoded CD19xCD3 T-cell engager)
• Early data and safety signals
• Novartis’s autoimmune focus
• Investing takeaways and the broader China biotech licensing trend
Podden och tillhörande omslagsbild på den här sidan tillhör
Mihir Otia. Innehållet i podden är skapat av Mihir Otia och inte av,
eller tillsammans med, Poddtoppen.
